Omega 3 fatty acids, gestation and pregnancy outcomes by Larque, Elvira et al.
Omega 3 fatty acids, gestation and pregnancy outcomes
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Abstract
Pregnancy is associated with a reduction in maternal serum docosahexaenoic acid (DHA, 22:6 n-3) percentage and its possible depletion in
the maternal store. Since the synthesis of long chain polyunsaturated fatty acids (LCPUFA) in the fetus and placenta is low, both the
maternal LCPUFA status and placental function are critical for their supply to the fetus. Maternal supplementation with DHA up to
1 g/d or 2·7 g n-3 LCPUFA did not have any harmful effect. DHA supplementation in large studies slightly the enhanced length of gestation
(by about 2 days), which may increase the birth weight by about 50 g at delivery. However no advice can be given on their general using to
avoid preterm deliveries in low or high risk pregnancies. Several studies, but not all, reported improvements of the offspring in some neu-
rodevelopmental tests as a result of DHA supplementation during gestation, or, at least, positive relationships between maternal or cord
serum DHA percentages and cognitive skills in young children. The effect seems more evident in children with low DHA proportions,
which raises the question of how to identify those mothers who might have a poor DHA status and who could benefit from such sup-
plementation. Most studies on the effects of n-3 LCPUFA supplementation during pregnancy on maternal depression were judged to be
of low-to-moderate quality, mainly due to small sample sizes and failure to adhere to Consolidated Standards of Reporting Trials guidelines.
In contrast, the effects of n-3 LCPUFA supplementation on reducing allergic diseases in offspring are promising.
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Numerous observational studies agree that fatty acid concen-
tration in maternal plasma increases during pregnancy as a
direct consequence of physiological gestational hyperlipide-
mia. Plasma triglyceride levels rise markedly during pregnancy
whereas the increase in the other lipid fractions is more mod-
erate(1,2). Phospholipids (PL) are the richest source of polyun-
saturated fatty acids (PUFA); during pregnancy, the increment
observed for docosahexaenoic acid (DHA, 22:6 n-3) concen-
tration was the highest for all PUFA in both maternal plasma
PL(3,4) and erythrocytes(5). The improved absolute maternal
DHA status in plasma PL can not be explained simply by
the modification of dietary habits, and the most accepted
hypothesis is the enhanced mobilization of DHA from
the maternal adipose tissue depots, although an increase in
the activity of the enzymes involved in their synthesis in the
mother can not be excluded(3). The placenta also partly regu-
lates the mobilization of fatty acids from adipose tissue
through leptin secretion to the maternal and fetal circula-
tion(6), although leptin resistance arises near the end of
pregnancy.
Despite the increase in the absolute concentrations, the rela-
tive amounts of the fatty acids show a different pattern; several
studies reported a continuous decline from the first trimester
until delivery in the percentage of DHA in maternal plasma
PL and erythrocytes(3,7), as well as in total plasma(7,8), respect
to the total fatty acid content; in addition, a reduction in the
overall functional essential fatty acid (EFA) status in maternal
plasma PL, reflected by the ratio between essential n-3 plus
n-6 and the non-essential n-7 plus n-9 unsaturated fatty(3,9),
might reflect the mother’s inability to mobilize adequate
amounts of long-chain polyunsaturated fatty acids (LCPUFA)
for optimal fetal development. These observations were con-
sistent across populations selected from five different
countries despite the variation in maternal EFA status between
countries(9). The high prenatal accumulation in the fetal brain
of DHA during the third trimester of pregnancy(10,11), the
selective and preferential maternal-fetal transfer of LCPUFA
across the placenta(12–18) and the low desaturase activity in
both placenta(19) and fetal liver(20) could explain this depletion
of LCPUFA in the maternal compartment. In recent years, great
attention has turned to considering whether low DHA intakes
in pregnant women may achieve an optimal central nervous
system development of the fetus(21).
Several studies pointed to an association between the per-
centage of maternal plasma DHA during gestation and the
development of cognitive functions in the neonate. The pre-
vious DHA status of the mother, the bioavalilability and
dose of LCPUFA used in the maternal supplements, and the
*Corresponding author: Elvira Larqué, fax 0034-868883963, email elvirada@um.es
British Journal of Nutrition (2012), 107, S77–S84 doi:10.1017/S0007114512001481


















Downloaded from https:/www.cambridge.org/core. IP address: 138.246.2.185, on 03 Mar 2017 at 15:52:03, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
functionality of the placenta could affect the fetal levels of
LCPUFA and their effect on neurodevelopment. Maternal
DHA supplementation during pregnancy significantly increased
maternal DHA percentages at delivery(22–29), while cord blood
DHA proportions increased in many of these studies(22,27) but
not in all(8,30). The association between maternal plasma DHA
status, the dietary intake of DHA during gestation, and the
development of cognitive functions in the neonate and there-
after in the child has been addressed in several human trials
(Table 1). Here, we discuss such studies and the potential
roles of LCPUFA supplementation during pregnancy under the
perspective of preventive nutrition.
The primary aim of this systematic review was to evaluate
the effects of maternal n-3 LCPUFA supplementation during
pregnancy on birth outcome (gestational length, birth weight,
birth length) as well as on the development of visual and other
neural functions in the offspring. The secondary aim was con-
cerned the effects of n-3 LCPUFA supplementation during preg-
nancy on biochemical markers related with the immunological
status in the mother or neonate as well as its influence on symp-
toms of maternal depression.
Methods
This paper represents a descriptive transversal study of the
results obtained from bibliographic research by means of a
systematic review. The selection of the articles was done
following the defined inclusion and exclusion criteria.
Inclusion criteria: The existence of any registry system of
data related to omega-3 fatty acids and pregnancy. We limited
the search to Randomized Controlled Trials and Humans. The
participants should be healthy pregnant women receiving any
n-3 LCPUFA supplementation during pregnancy or pregnancy
þ lactation. The studies must have come from original articles
published by peer-review journals.
Exclusion criteria: Studies on n-3 LCPUFA supplementation
that started after delivery in children or mothers. Articles avail-
able only in abstract form. Papers not written in English, Span-
ish, French or German language.
Descriptors used
The cut-off date for papers was 1st March 2011. The study of
the hierarchical structure of the Thesaurus “Medical Subject




The most important biomedical databases where consulted
(e.g. MEDLINE, The Cochrane Library, LILACS and ISI Web of
Sciences).
Search equations
“Omega-3 fatty acids and Pregnancy”. Limits Activated:
Humans, Randomized Controlled Trial.
Table 1. Randomized controlled trials of n-3 LCPUFA supplementation in healthy pregnancies on birth outcomes
Study Participants Daily Dose Duration Primary functional outcome
DOMINO study
Makrides et al. 2010(34)
2399 0·8g DHA þ 0·1g EPA Week 22 to delivery Longer gestation and increased
birth weight
POSGRAD study
Ramakrishan et al. 2010(35)
Stein et al. 2010(78)
370 400mg DHA Week 18 to delivery
In primigravid, higher birth weight and
head circumferenceGreater length of
chidren at 18 months
Bergman et al. 2007(79)




Week 21 -3 months
post-delivery
Gestational length, birth weight or
length (n.s)
Reduced BMI at 21 months
Innis and Friesen 2008(21) 135 400 mg DHA Week 16 to delivery Gestational length, birth weight
or length (n.s.)
Danish Cohort 1·1g DHA þ 1·6g EPA Week 30 to delivery
Olsen et al. 1992(36) 533 olive oil Longer gestation and increased
birth weight
Knudsen et al. 2006(38) 3098 0·1, 0·3, 0·7, 1·4g,
2·8g DHA þ EPA
week 17-27 to delivery Gestational length (n.s)
Nuheal study 195 0·5g DHA
400ug MTHF MTHF þ DHA
Week 22 to delivery
Krauss-Etchsmann
et al. 2007(27)
Gestational length and birth weight (n.s)
Krauss-Etchsmann
et al. 2008(73)
Reduced Th2 inflammatory cytokines
in cord
Smuts et al. 2003(39) 53 135 mg DHA
18 mg DHA
Weeks 24-28 to delivery Longer gestation and increased
birth weight
Helland et al. 2001(37) 341 1·18g DHA þ 0·8g EPA Week 18 to 3 months
post-delivery























Downloaded from https:/www.cambridge.org/core. IP address: 138.246.2.185, on 03 Mar 2017 at 15:52:03, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
The search made in the different databases provided 88
articles. 80 articles were found in PUBMED, which included all
those found in ISI Web of Knowledge. From this bibliographic
list of articles, 23 references were included because they fullfilled
the inclusion criteria for the primary objectives of this systematic
review, while the rest of the documents were only related
articles. In addition, 7 articles were found in LILACS but none
fell within the inclusion criteria. One Cochrane review was
also identified on the effects of maternal n-3 supplementation
during pregnancy.
Two different reviewers (EL and AG) evaluated the concor-
dance and discrepancy of the bibliographical search. In Table 1
we present a summary of the following data: Study (first author
and year of publication), dose of the n-3 LCPUFA supplements
used, time of supplementation, and primary outcome results.
Results and Discussion
No harmful effect on in the mother or the neonate of n-3
LCPUFA supplementation during pregnancy was mentioned.
The effect on maternal hypercholesterolemia and hypertrigly-
ceridemia associated with gestation was low; the intake of 4 g/
d fish oil did not alter triacylglycerols, total cholesterol, HDL
or LDL-cholesterol during pregnancy in maternal serum or in
cord blood compared with the effect of olive oil(31). In addition,
no changes were observed in maternal blood pressure(31,32).
The consensus recommendations of a panel of experts on
behalf of the European Commission is that pregnant women
should have an average dietary intake of at least 200 mg
DHA/d; intakes of up to 1 g/d DHA or 2·7 g/d n-3 LCPUFA
have been used in randomized clinical trials with no significant
adverse effects(33).
Table 1 details the randomized controlled trials until March
2011 that evaluated the effect of n-3 LCPUFA supplementation
during pregnancy on birth outcomes; in some of them a
follow up of the cohort was reported. In table 2, we included
the randomized controlled trials that have evaluated the effect
of n-3 LCPUFA supplementation during pregnancy on the neur-
onal function of the offspring.
Birth Outcomes
Several studies showed that the maternal intake of n-3 LCPUFA
during pregnancy resulted in a slightly longer gestation period
and somewhat higher birth weight (Table 1). The sample size
is critical for identifying differences in these variables, and
large studies such as DOMINO(34), POSGRAD(35), or the
Danish Cohort(36) found differences in birth outcomes as a
result of n-3 supplementation during pregnancy (Table 1). It is
important to consider that the higher birth weight reported for
n-3 LCPUFA supplementation during pregnancy was probably
due to the greater length of these pregnancies, since the differ-
ences in birth weight disappeared when using the gestational
age as covariable(34). Helland et al (37) did not find differences
in the duration of gestation or birth weight in 341 subjects
(148 subjects receiving cod liver with 1·18 g DHA þ 0·8 g EPA
vs. 137 subjects receiving corn oil); nevertheless, when they
compared the quartile with the highest concentration of DHA
Table 2. Randomized controlled trials of n-3 LCPUFA supplementation during pregnancy on neurodevelopmental function of the offspring
Study Participants Daily dose Duration Primary functional outcome
DOMINO study
Makrides et al 2010(34)
2399 0·8g DHA þ 0·1g EPA Week 22 to delivery Language or cognitive skills
at 18 months (n.s.)
Postpartum maternal depression (n.s.)
Innis and Friesen 2008(21) 135 400 mg DHA Week 16 to delivery More girls in placebo than in the DHA group
had visual acuity
below average at 2 months
Judge et al 2007b(56) 29 0·214 g DHA Week 24 to delivery Problem-solving improved at 9 months.
Fagan test of infant intelligence (n.s)
Judge et al 2007a(54) 30 Visual acuity (Teller cards) improved
at age 4 months;
at age 6 months (n.s)
Tofail et al 2006(58) 249 1·2g DHA þ1·8g EPA Week 25 to delivery Bayley MDI and PDI at age 10 months (n.s)
0·27g ALA þ2·3g LA Associations by multiple regression analyses
Colombo et al 2004(57) 77 135 mg DHA
35 mg DHA
Weeks 24-28 to delivery Mental processing improved at 4 and
6 months but not at 8 months.
Increase in examining and less distractibility
between age 1 and 2y; attentional
disengagement (n.s.).
Dunstan et al 2008(55) 72 2·2g DHA þ1·1g EPA Week 20 to delivery Eye-hand coordination favored at 2·5 years.
Malcolm et al. 2003a(53) 100 200 mg fish oil Week 15 to Visual acuity (VEP, ERG) (n.s.).
Malcolm et al. 2003b(30) delivery Correlations VEP and ERG with infant DHA
Helland et al 2001(37) 341 1·18g DHA þ 0·8g EPA Week 18 to
3 months post-delivery
EEG and Fagan test (n.s.) during the 1st year.
Correlation of EEG on day 2 and cord DHA
Helland et al. 2003(50)
(4-year)
84 IQ at age 4y favoured with DHA
Correlation of IQ with maternal DHA intake
Helland et al. 2008(51)
(7-year)
142 IQ (n.s.). Significant correlation at age 7 with
maternal DHA during pregnancy
(n.s.) not significant; VEP, visual evoked potentials; ERG, electroretinogram; EEG, electroencephalography; MDI, mental development score; PDI, psychomotor development
score.
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in umbilical plasma phospholipids with the quartile with the
lowest concentration of DHA, they found a longer gestational
period in the group of babies with higher DHA cord concen-
tration. In addition, Knudsen et al.(38) suggested that the effect
of n-3 LCPUFA on the length of gestation could be a “quick-
acting” effect, since they did not find any association between
the intake of n-3 LCPUFA or a-linolenic acid and the timing of
spontaneous delivery in their study in which a large proportion
of the women stopped taking the capsules before they deliv-
ered. For smaller studies, limitations in their statistical power
for such variables could explain the lack of differences for
these parameters(21,22,27,39).
The results on higher birth weight and length of gestation
were also confirmed in different meta-analyses about the
effects of n-3 LCPUFA supplementation during preg-
nancy(40–42). Szajewska et al (41) reported that n-3 LCPUFA
supplementation during pregnancy (1278 infants from
6 randomized controlled trials) enhanced the duration of the
pregnancy by an average of 1·6 days, and head circumference
was also 0·26 cm greater in the supplemented group. In the
Cochrane review(40), covering 6 trials involving 2783 women,
marine oil supplementation during pregnancy resulted in a
mean gestation that was 2·6 days longer for these subjects
than for women allocated to placebo or no treatment, and the
birth weight was slightly higher (weight mean difference 47 g,
95 % CI 1-93 g; 3 trials, 2440 women). Recently, Salvig &
Lamont(42) also reported higher birth weight (71 g) in women
who received n-3 fatty acids during pregnancy compared with
a placebo (3 RCT involving 1187 women), and a longer gesta-
tional period (4·5 days). However, its effect on the rate of pre-
term birth is controversial; only Salvig et al.(42) reported a
significant reduction of preterm births (,37 weeks) while
the reduction of early preterm birth (,34 weeks) was found
to be significant in two of these meta-analyses(40,42). However,
the rate of low birth weight (,2500 g) was not statistically
different in any of the 3 meta-analyses(40–42).
Although the effect of n-3 LCPUFA supplementation in high
risk pregnancies is not mainly addressed in this systematic
review, the results in this respect are controversial. In a Euro-
pean Multicenter Trial(43) involving women with a preterm
delivery history, those randomly assigned to receive an n-3
LCPUFA supplement (0·9 g DHA þ 1·3 g EPA) had significantly
lower rate of recurrent preterm delivery before 37 weeks
(mean difference 0·54 %, 95 % CI 0·30-0·98) and before 34
weeks. Moreover, in a prospective cohort study in Denmark
with 8729 pregnant women, the low consumption of fish was
a strong risk factor for preterm delivery and low birth
weight(44). However, recently, Harper et al (45) did not report
changes in gestational length, birth weight or length in pregnant
women receiving 17-a-hydroxyprogesterone caproate plus
800 mg/d DHA þ 1·2 g EPA to prevent recurrent preterm birth.
In addition, the daily intake of either 3 g EPA or placebo did
not prevent the recurrence of intrauterine growth retardation
or pregnancy induced hypertension in 63 subjects with high
risk pregnancies. The results of the meta-analyses showed no
clear difference in the relative risk of birth before 37 completed
weeks in high risk pregnancies(40,46). Thus, using n-3 LCPUFA
supplements to reduce the risk of preterm birth, low birth
weight or small-for-gestational age is still controversial,
although a slight effect remains a possibility.
Effects on visual and cognitive functions
To date, no meta-analyses on the effect of the maternal intake
of n-3 fatty acids during pregnancy on the visual or cognitive
functions of the offspring have been published. Two
Cochrane reviews are available on the effects of infant for-
mulas supplemented with n-3 LCPUFA after birth in term
and preterm babies but this is beyond our scope(47,48).
The available results of the present systematic review suggest
some association between early DHA status and cognitive func-
tion in infancy and early childhood (Table 2). Helland et al.(37)
reported that 1·18 g of DHA supplementation during pregnancy
did not change electroencephalogram tests on the second day
of life or the results of the Fagan test of intelligence at 27 and
39 weeks of age; however, neonates with mature electroence-
phalography scores had a higher concentration of DHA in umbi-
lical plasma phospholipids. The Fagan test of infant cognitive
function is predictive for IQ at an older age, and is comparable
to the Bayley test(49). Since it is more difficult to detect small
differences in neurodevelopment early in life with these tests
than later on when children are older, these authors are engaged
in following up this cohort of children. In fact, at 4 years of age,
these authors reported improved results in the Kaufmann ABC
test of cognitive development in children from mothers receiv-
ing DHA supplements(50), and significant correlations for IQ in
the sequential processing at 7 years of age with maternal DHA
proportions(51).
Rudimentary forms of various attentional functions are pre-
sent at birth, but each of the functions exhibits different and
apparently dissociable periods of postnatal change during
the first years of life.(52). Malcolm et al. demonstrated an
association between DHA status of term infants and retinal
sensitivity within the first week of life(53), as well as visual
evoked potential (VEPs) at 1 year old (50 weeks), and 66
weeks post-conceptional age(30), although no differences
between supplemented and placebo groups were reported.
Other studies also reported improved visual acuity (Teller
cards) at 4 months but not at 6 months(54), and even improved
eye-hand co-ordination at the age of 2·5 years(55). In this line,
Judge et al. pointed to a benefit for problem-solving skills but
not for recognition memory at 9 months of age(56). Problem
solving requires that an infant both remember that a toy is
hidden and be able to pay sufficient attention to execute a
series of steps to achieve a goal. This result complemented
the report of improved mental processing at 4 years(50).
Some authors did not find improvements of neurodevelop-
mental tests as a result of HA supplementation versus placebo
during gestation(57,58), but regression analyses showed
maternal DHA percentages positively related to measurements
of central nervous system development in these studies. In the
DOMINO study, no effect of DHA treatment during pregnancy
on early childhood cognitive or language scores was reported;
fewer children in the DHA treated group had delayed cogni-
tive development compared with the control group, and
girls exposed to higher-dose DHA in utero had lower
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language scores than girls from the control group(34), pointing
to an interaction with the sex of the children. It has been
suggested that the effects of n-3 fatty acids on neurodevelop-
ment might meet a saturation point, above which no further
effect of LCPUFA n-3 could be detected(21).
Observational longitudinal studies have also supported a
relationship between DHA status and infant development; in
Inuits from Arctic Quebec, cord DHA levels were associated
with greater visual, cognitive and motor development during
the first year of life(59), as well as shorter latencies of VEP in
school-age children(60). Further support for the importance of
DHA availability in early life comes from the positive associ-
ations between maternal fish consumption during pregnancy
and cognitive performance of the offspring, observed in large
birth cohorts such as ALSPAC(61), VIVA(62) and the Danish
National Birth Cohort(63). However, these results should be
interpreted with caution, considering the limitations of observa-
tional studies which often cannot fully adjust for all confound-
ing variables.
A novel approach has been proposed to check whether a
poor DHA status sufficient to delay infant development
occurs among pregnant women. In this sense, an increased
risk of low visual acuity scores among infants at 2 months of
age born to mothers following their usual diet was reported
compared with infants of women considered at low risk of
inadequate DHA due to DHA supplementation(21). Some preg-
nant women seem to be DHA-deficient and further studies
should addressed to ascertain the dietary n-3 LCPUFA require-
ments during pregnancy, identificatying the asymptote in
functions above which no further benefits occurs.
Effects on maternal depression and infant immunity
The effect of DHA supplementation during pregnancy on
maternal depression has been addressed in very few studies,
most of them with a small sample size, possibly non-specific
and without placebo comparison. No clear benefit was
observed in these studies. Four of these studies did not find sig-
nificant effect of DHA supplementation taken for 6 or 8 weeks
during pregnancy in subjects with diagnosed major depression
in studies involving a small number of participants(64–67). Only
Su et al.(68) with 36 depressed subjects receiving 1·2 g
DHA þ 2·2 g EPA found reduced depression scores, although
no placebo group was included in this study.
In healthy pregnant women, no effect on postpartum
maternal depression was found in a study with a small
number of subjects(69), or in a large study (DOMINO study)
involving more than 2000 participants(34). Recently, Jans
et al.(70) performed a meta-analysis including 7 randomized
controlled trials, in which a total of 309 women taken
n-3 fatty acid supplementation were compared with 303
women following a placebo treatment, and no significant
effect was found on post-treatment maternal depression
(95 % CI - 0·18, 0·13; P¼0·76). The quality of research in this
area needs to be improved.
Concerning the effect of n-3 LCPUFA supplementation in
healthy pregnancies and on the immunological function, positive
effects were reported concerning a reduction in food allergy risk
and Ig E associated eczema in infants during the first year of
life(71), and reduced proinflammatory cytokines and Th2 promot-
ing prostaglandin E2 in the mother(72). These results were also
supported by Krauss-Etschmann et al.(73), who observed reduced
Th2 inflammatory cytokines in cord blood during the NUHEAL
study. From the Danish cohort, a lower rate of allergic asthma
was observed in 16 year old children born to mothers receiving
supplementation with fish oil compared with olive oil(74). For
infants with a family history of allergic disease, maternal n-3
LCPUFA supplementation during pregnancy also decreased the
risk of food allergy and Ig E eczema during the first year of
life(71,75) and improved the cord blood cytokine pattern(76,77).
In conclusion, n-3 LCPUFA supplementation during preg-
nancy has a moderate effect on higher length of gestation
and birth weight, but not enough for general recommendation
in order to avoid preterm deliveries. Most of the papers found
significant differences in some visual or cognitive tests in the
offspring or, at least, positive associations between DHA
status in the neonate and pregnant mother and neurodevelop-
mental outcomes. LCPUFA supplementation, in addition to an
already adequate omnivorous diet, may not yield any measur-
able benefit, but very low LC-PUFA intakes could result in loss
of function that could even be of major importance in prema-
turely born babies. The effect of n-3 LCPUFA supplementation
during pregnancy on depressive symptoms has been evalu-
ated in studies with too many limitations to achieve a final
conclusion, although no effect was observed in these prelimi-
nary studies. In contrast, its effects on reducing allergic bio-
markers in children seem very promising.
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